The Global Telmisartan
Market, by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension,
Cardiac Arrest, and Stroke,), by Composition (Single and Combinational), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), was valued at US$ 3,880.9 million in 2017, and is projected to
exhibit a CAGR of 1.4% over the forecast period (2018 - 2026).
Telmisartan is a prescription
medication often prescribed to relax and widen blood vessels in persons with
high blood pressure. Telmisartan belongs to a group of drugs called angiotensin
II receptor blockers (ARBs). Telmisartan may be used alone or in combination
with other medications such as hydrochlorothiazide for treatment of high blood
pressure. Increasing awareness regarding hypertension and its management by
organizing global campaigns are expected to drive growth of the market. For
instance, in May 2017, Argentinian Society of Hypertension (SAHA) participated
in global campaigns named May Measurement Month and World Hypertension Day for
creating awareness among population related to blood pressure and their
management.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2524
Browse 23 Market Data Tables and
19 Figures spread through 157 Pages and in-depth TOC on ”Global Telmisartan
Market" by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension,
Cardiac Arrest, and Stroke), by Composition (Single and Combinational), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) - Global Forecast to 2026"
Key players are focused on
development and launch of new generic product to maximize access to end users
for their product in less cost, in turn gaining market share in telmisartan
market. For instance, in June 2017,
Solco Healthcare, announced its FDA approval for Telmisartan tablets, 20mg,
40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer
Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles
for all three strengths. Moreover, increasing government initiatives for
hypertension management is expected to drive growth of the global Telmisartan
market. For instance, in December 2017, the Secretary, Ministry of Health and
Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and
Director General, Indian Council of Medical Research (ICMR) launched, the India
Hypertension Management Initiative (IHMI). The IHMI aims to reduce disability
and death related to cardiovascular disease (CVD), by improving control over
high blood pressure (hypertension), reducing salt consumption from food, and
eliminating artificial trans-fats, which are leading risk factors for
developing CVD.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/telmisartan-market-2524
Key Takeaways of the Telmisartan
Market:
The global telmisartan market is
expected to expand at a CAGR of 1.4% during the forecast period (2018 – 2026),
owing to continuous marketing approvals for telmisartan.
Among strength, 80 mg segment is
expected to hold leading position in the global telmisartan market, owing to
approval from USFDA of telmisartan 80 mg in combination with other drugs. For
instance, in September 2016, Nippon Boehringer Ingelheim Co., Ltd. and Astellas
Pharma Inc. received the manufacturing and marketing approval for Micatrio
combination tablets from US FDA. Tablet comprises of telmisartan (concentration
80mg), amlodipine besylate, and hydrochlorothiazide (HCTZ). Such manufacturing
and marketing approvals for telmisartan promote their growth in global market
during the forecast period.
Major players operating in the
global telmisartan market include C.H. Boehringer Sohn AG & Ko. KG,
Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S.,
Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co.,
Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2524
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment